CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Yongxian Hu, Yali Zhou, Mingming Zhang, Wengang Ge, Yi Li, Li Yang, Guoqing Wei, Lu Han, Hao Wang, Shuhui Yu, Yi Chen, Yanbin Wang, Xiaohong He, Xingwang Zhang, Ming Jing Gao, Jingjing Yang, Xiuju Li, Jiangtao Ren, He Huang
The abstract is not reproduced here because its license does not permit redistribution. Read it at the original source.
Record
- Archive ID
- doi:10.1158/1078-0432.ccr-20-3863
- Published
- Feb 24, 2021
- Venue
- Clinical Cancer Research
- DOI
- 10.1158/1078-0432.ccr-20-3863
- PubMed
- 33627493
- Categories
- CAR-T cell therapy research
- Provenance
- openalex